Speaker Profile

Ph.D., CEO, Mekonos

Biography
Dr. Anil Narasimha is an accomplished scientist and founder in the field of personalized medicine. He co-founded Mekonos in 2017 to come up with a platform to automate delivery of payloads into fragile cell types while remaining precise and scalable. Prior to Mekonos, Anil completed his PhD at UC San Diego before moving to Stanford University to become a postdoctoral fellow in Dr. Michael Snyder's laboratory. There, he was introduced to cell and gene therapy and identified some of the pitfalls associated with it, including the lack of automation and precision when it came to delivering payloads into primary cells. His goal is to utilize his platform to make cell and gene therapies more accessible.

Talk
Ex-vivo Silicon-based Delivery of Macromolecules into Cells
At Mekonos, we are developing a platform for delivery of payloads into cells in a precise, efficient, and automated manner. We take advantage of scalable silicon technology to create a method that is advantageous for complex gene editing, targeted delivery, and dose control at the single cell level.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chair:
Vanessa Soros, Graphite Bio

Sessions:

  • Gene & Cell Therapies Overview
    - Janice Chen, Mammoth
  • Cutting Edge Technologies for Gene Engineering and Cell Therapy (PANEL)
    Session Chair: Vanessa Soros, Graphite Bio
    - Mark McKee, Intellia Tx
    - Amy Simon, Beam Therapeutics
    - Eric Ostertag, Poseida Therapuetics
  • Translating CGT to the Clinic (PANEL)
    Session Chair: Nicole K. Paulk, UCSF
    - Matthew Porteus, Stanford
    - Peter Francis, 4D Molecular Therapeutics
    - Erandi De Silva, Forge Biologics
    - Patrice Hugo, Q2 Solutions
    - Susanne Fors, Ultragenyx
  • PMWC Showcase
    - Yuri Fesko, Labcorp
    - Yan Zhang, Mission Bio
    - Anil Narasimha, Mekonos Inc.
    - Emily Anderson, Horizon, a PerkinElmer Company
    - Jesse Salk, Twinstrand
    - William Shrader, AcureX Therapeutics
  • Emerging Gene Therapies for Epidermolysis Bullosa
    - Peter Marinkovich, Stanford
  • Past, Present and Future of CRISPR Where will CRISPR Take Us and How is the Technology Evolving to Realize its Full Potential (PANEL)
    Session Chair: Janice Chen, Mammoth
    - Kiana Aran, Cardea Bio
    - Mark McKee, Intellia Tx
    - Josh Lehrer, Graphite Bio